Interestingly, we demonstrated that CB2 stimulation with its selective agonist, JWH-133, restored the inflammatory state, normally impaired in IBD, reducing both IL-6 and IL-23 levels, and increasing IL-13 release both in UC and CD macrophages, suggesting these cytokines as primary targets of CB2 in IBD. Here, IL6 is linked to inflammatory bowel disease.